Etoposide Plus Radiation Therapy Followed by Combination Chemotherapy in Treating Children With Newly Diagnosed Advanced Medulloblastoma
Brain Tumors, Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain Tumors focused on measuring untreated childhood medulloblastoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically diagnosed advanced (high grade) childhood medulloblastoma Residual disease of at least 1.5 cm2 in size on MRI or CT scan OR Evidence of CNS or extraneural metastases PATIENT CHARACTERISTICS: Age: 3 to 21 Performance status: Not specified Life expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm^3 Platelet count at least 100,000/mm^3 Hepatic: SGPT less than 5 times normal Bilirubin less than 1.5 mg/dL Renal: Creatinine less than 1.7 mg/dL OR Creatinine clearance greater than 70 mL/min Other: Not pregnant or nursing Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Prior corticosteroids allowed Radiotherapy: No prior radiotherapy Surgery: Not specified
Sites / Locations
- University of Alabama at Birmingham Comprehensive Cancer Center
- MBCCOP - Gulf Coast
- Arizona Cancer Center
- University of Arkansas for Medical Sciences
- University of California San Diego Cancer Center
- Lucile Packard Children's Hospital at Stanford
- Sutter Cancer Center
- University of California Davis Medical Center
- Kaiser Permanente-Southern California Permanente Medical Group
- Children's Hospital and Health Center
- Naval Medical Center - San Diego
- Kaiser Permanente Medical Center - Santa Clara
- Yale Comprehensive Cancer Center
- Walter Reed Army Medical Center
- Shands Hospital and Clinics, University of Florida
- Nemours Children's Clinic
- Sylvester Cancer Center, University of Miami
- Miami Children's Hospital
- Walt Disney Memorial Cancer Institute
- CCOP - Florida Pediatric
- St. Mary's Hospital
- Emory University Hospital - Atlanta
- Cancer Research Center of Hawaii
- Tripler Army Medical Center
- Rush-Presbyterian-St. Luke's Medical Center
- Children's Memorial Hospital, Chicago
- Hope Children's Hospital
- Saint Jude Midwest Affiliate
- University of Kansas Medical Center
- CCOP - Wichita
- Via Christi Regional Medical Center
- MBCCOP - LSU Health Sciences Center
- Tulane University School of Medicine
- CCOP - Ochsner
- Eastern Maine Medical Center
- Maine Children's Cancer Program
- Marlene & Stewart Greenebaum Cancer Center, University of Maryland
- Johns Hopkins Oncology Center
- Boston Floating Hospital Infants and Children
- Massachusetts General Hospital Cancer Center
- Dana-Farber Cancer Institute
- University of Massachusetts Memorial Medical Center
- Children's Hospital of Michigan
- St. John's Hospital and Medical Center
- Hurley Medical Center
- University of Mississippi Medical Center
- Keesler Medical Center - Keesler AFB
- University of Missouri-Columbia Hospital and Clinics
- Cardinal Glennon Children's Hospital
- Washington University School of Medicine
- Norris Cotton Cancer Center
- CCOP - Northern New Jersey
- Hackensack University Medical Center
- University of New Mexico School of Medicine
- Roswell Park Cancer Institute
- Schneider Children's Hospital
- Mount Sinai School of Medicine
- University of Rochester Cancer Center
- State University of New York Health Sciences Center - Stony Brook
- State University of New York - Upstate Medical University
- Mission Saint Joseph's Health System
- Carolinas Medical Center
- Presbyterian Healthcare
- Duke Comprehensive Cancer Center
- East Carolina University School of Medicine
- Comprehensive Cancer Center at Wake Forest University
- Oklahoma Memorial Hospital
- Natalie Warren Bryant Cancer Center
- CCOP - Columbia River Program
- Legacy Emanuel Hospital and Health Center
- St. Christopher's Hospital for Children
- Medical University of South Carolina
- Children's Hospital of Greenville Hospital System
- James H. Quillen College of Medicine
- Saint Jude Children's Research Hospital
- Medical City Dallas Hospital
- Simmons Cancer Center - Dallas
- Cook Children's Medical Center - Fort Worth
- University of Texas Medical Branch
- Baylor College of Medicine
- San Antonio Military Pediatric Cancer and Blood Disorders Center
- MBCCOP - South Texas Pediatric
- University of Texas Health Science Center at San Antonio
- Scott and White Clinic
- Vermont Cancer Center
- Inova Fairfax Hospital
- Naval Medical Center, Portsmouth
- Massey Cancer Center
- Carilion Roanoke Community Hospital
- Madigan Army Medical Center
- West Virginia University Medical School-Charleston
- West Virginia University Hospitals
- St. Vincent Hospital
- Midwest Children's Cancer Center
- Alberta Children's Hospital
- Cross Cancer Institute
- Children's Hospital
- Children's Hospital of Eastern Ontario
- Hospital for Sick Children
- McGill University Health Center - Montreal Children's Hospital
- Hopital Sainte Justine
- Centre Hospitalier de L'Universite Laval
- Academisch Ziekenhuis Groningen
- San Jorge Childrens Hospital
- Swiss Pediatric Oncology Group Bern
- Clinique de Pediatrie
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Treatment 1, Etoposide, 50mg/m2/day
Treatment 2, Etoposide, 35mg/m2/day
Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7). Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51).
Patients begin treatment within 1 month of surgery. Patients receive 6 weeks of radiation therapy to the head and spine, with boosts to the posterior fossa and to sites of metastasis. Patients also receive 2 courses of oral etoposide once daily for 3 weeks concurrent with and immediately following radiotherapy (weeks 1-3 and 5-7). Patients then receive adjuvant chemotherapy consisting of cisplatin IV once every 4 weeks for 3 courses beginning on week 11, oral etoposide daily for 21 days every 4 weeks for 3 courses (weeks 11, 15, and 19), cyclophosphamide IV on days 1 and 2 with filgrastim (G-CSF) SQ daily for at least 10 days every 4 weeks for 8 courses (weeks 23-51), and vincristine IV on days 1, 8, and 15 every 4 weeks for 8 courses (weeks 23-51).